维持性血液透析患者血浆正五聚蛋白的变化与心血管事件危险因素的相关性

陈静; 陈奕鸣; 杨晶; 李胜开; 孙京华; 蒋甘孺; 尹忠诚

doi:10.3969/j.issn.1671-4091.2020.03.010

中国血液净化 >

2020 , Vol. 19 >Issue 03: 183 - 186

DOI: https://doi.org/10.3969/j.issn.1671-4091.2020.03.010

临床研究

维持性血液透析患者血浆正五聚蛋白的变化与心血管事件危险因素的相关性

陈静 ,
陈奕鸣 ,
杨晶 ,
李胜开 ,
孙京华 ,
蒋甘孺 ,
尹忠诚

展开

1徐州医科大学附属医院肾内科

收稿日期: 2019-10-28

修回日期: 2019-12-10

网络出版日期: 2020-03-12

收起

Changes of plasma PTX3 in maintenance hemodialysis patients and their correlation with cardiovascular disease risks

CHEN Jing ,
CHEN Yi-Ming ,
YANG Jing ,
LI Sheng-Kai ,
SUN Jing-Hua ,
JIANG Gan-Ru ,
YIN Zhong-Cheng

Expand

1 Department of Nephrology, Xuzhou Medical University Affiliated Hospital, Xuzhou 221006, China

Received date: 2019-10-28

Revised date: 2019-12-10

Online published: 2020-03-12

Fold

摘要

【摘要】目的探讨维持性血液透析(maintenance hemodialysis,MHD)患者血浆正五聚蛋白3(pentraxin3, PTX3)的变化与心血管事件危险因素的相关性。方法将2019 年3 月～7 月于徐州医科大学附属医院行MHD 的80 例患者纳入实验组，所有患者均接受持续≥6 个月的血液透析治疗，根据有无心血管疾病分为心血管疾病(cardiovascular diseases,CVD)组和无心血管疾病(non cardiovascular diseases, NCVD)组。选取同期徐州医科大学附属医院健康体检者20 例纳入对照组。采用酶联免疫吸附法测定血浆PTX3。用Spearman 相关分析PTX3 与超敏C 反应蛋白(high sensitivity C-reactive protein, hsCRP)、肌钙蛋白T(troponin T,cTnT)、血红蛋白(Hemoglobin,Hb)等指标的关系。用Logistic 回归分析CVD 发生的危险因素。结果MHD 组患者血浆PTX3 水平明显高于健康对照组(t=- 7.346, P ＜0.001)，CVD 组血浆PTX3 水平明显高于NCVD 组(t=-4.208,P＜0.001)。结论维持性血液透析患者PTX3 水平较正常人升高，合并CVD 的血浆PTX3 水平显著高于NCVD 的患者，年龄、cTnT、PTX3 是MHD 患者并发CVD 独立危险因素(OR 值分别为1.070，1.019，4.338；95% CI 分别为1.003～1.141，1.004～1.035，1.160～16.608；P 值分别为0.039，0.013，0.029)。

关键词： 维持性血液透析; 心血管疾病; 危险因素; 正五聚蛋白3

本文引用格式

陈静 , 陈奕鸣 , 杨晶 , 李胜开 , 孙京华 , 蒋甘孺 , 尹忠诚 . 维持性血液透析患者血浆正五聚蛋白的变化与心血管事件危险因素的相关性[J]. 中国血液净化, 2020 , 19(03) : 183 -186 . DOI: 10.3969/j.issn.1671-4091.2020.03.010

Abstract

【Abstract】Objective To investigate the relationship between changes of plasma positive pentraxin 3 (PTX3) and cardiovascular disease risks in maintenance hemodialysis (MHD) patients. Methods Eighty patients undergoing MHD in our hospital from March 2019 to July 2019 were enrolled as the experimental group. All patients received hemodialysis for ≥6 months. According to the presence or absence of cardiovascular disease, they were assigned into cardiovascular disease (CVD) group or non- cardiovascular disease (NCVD) group. Twenty individuals with healthy physical examination in our hospital were enrolled as the control group. Plasma PTX3 was determined by enzyme-linked immunosorbent assay. Spearman correlation was used to analyze the relationship between PTX3 and high-sensitivity C-reactive protein (hsCRP), troponin T (cTnT), and hemoglobin (Hb). Risk factors for CVD were analyzed by two- class logistic regression. Results Plasma PTX3 level was significantly higher in the MHD group than in the healthy control group (t=-7.346, P<0.001), as well as in the CVD group than in the NCVD group (t=-4.208, P<0.001). Conclusion Plasma PTX3 was higher in MHD patients than in normal subjects, and was significantly higher in MHD patients complicated with CVD than those without CVD. Age (OR=1.070, 95% CI: 1.003- 1.141, P=0.039), cTnT (OR=1.019, 95% CI: 1.004-1.035, P=0.013), and PTX3 (OR=4.338, 95% CI: 1.160-16.608, P=0.029) were the independent risk factors for CVD in MHD patients.

Key words： Maintenance hemodialysis; Cardiovascular disease; Risk factors; Pentraxin 3

参考文献

1. 王韫芳, 杨冉，薄庆. 终末期肾病患者死亡的相关因素研究[J].安徽医药，2016.20(2):324-327.
2. Shi K, Wang F, JiangH，et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients[J].Dig Dis Sci,2014.59(9):2109-17.
3. Jaillon, Sebastien, Moalli et al. The humoral pattern recognition molecule PTX3 Is a key component of innate immunity against urinary tract infection 〔J〕.Immunity, 2014,40(4):621-632.
4. Presta M，Camozzi M，Salvatori G，et al. Role of the soluble pattern recognition receptor PTX3 in vascular biology[J].Cell Mol Med, 2010，11(4):723-738.
5. Guo T, KeL，QiB，et al. PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophagess[J].Journal of Clinical Immunology，2012，32(2):330-339.
6. Weiner DE，Dad T.Stroke and chronic kidney disease: Epidemiology, pathogenesis, and management across kidney disease stages[J].Seminars in Nephrology, 2015，35(4):311-322.
7. Benitez R, Delgado-Maroto V，Caro M，et al.Vasoactive intestinal peptide ameliorates acute myocarditis and atherosclerosis by regulating inflammatory and autoimmune responsess[J].Immunol，2018，200(11):1800122.
8. Nishi K, Imamura T，Kitamura K，et al. Associations of plasma pentraxin3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease[J].RenFail,2011，33(4):398-404.
9. 李巧思, 毕国荣，张晓天,等. 脑梗死血浆正五聚蛋白3的动态改变及与颈动脉不稳定斑块的关系[J].中国神经精神疾病杂志，2017，43(3):129-134.
10. Boehme M, Kaehne F，Kunhne A，et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease[J].Nephrol Dial Transplant, 2007，22(8): 2224-2229.
11. Matsui S, Ishii J, Kitagawa F，et al.Pentraxin3 in unstable angina and non-ST-segment elevation myocardial infarction[J]. Atherosclerosis, 2010，210(1): 220-225.
12. Witasp A, Ryden M，CarreroJJ，et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: A reflection of endothelial dysfunction[J].Obesity, 2013，8(5): 63493.
13. Shishkina VS, Toklueva LR，Kashirina SV, et al. Comparison of morphological features of carotid arteries atherosclerotic plaques with clinical-instrumental data in symptomatic and asymptomatic patients with severe carotid atherosclerosiss[J]. Kardiologiia, 2013，53(4):25-31.
14. Bazan HA, Smith TA，Donovan MJ，et al. Future management of carotid stenosis: role of urgent carotid interventions in the acutely symptomatic carotid patient and best medica therapy for asymptomatic carotid disease[J].Ochsner Journal, 2014，14(4): 608.
15. Ryu, WS, Kim CK，Kim BJ, et al. Pentraxin3: a novel and independent prognostic marker in ischemic stroke[J]. Atherosclerosis, 2012，220(2):581-586.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献